Table 1 Clinicopathological characteristics of donors included in this study

Number

5

2

3

5

5

5

3

Age of death (mean ± SD)

80 ± 7

75 ± 2

80 ± 3

81 ± 6

81 ± 7

83 ± 4

66 ± 6*

M/F

2/3

2/0

0/3

3/2

4/1

4/1

1/2

Age of onset (mean ± SD)

n.a

68 ± 2

70 ± 4

70 ± 7

70 ± 6

75 ± 4

58 ± 5

Disease duration (mean ± SD)

n.a

6 ± 4

10 ± 7

11 ± 5

10 ± 3

9 ± 4

8 ± 3

Time to onset dementia (mean ± SD)

n.a

n.a

0

n.a

6 ± 2

0 ± 1

n.a

Postmortem delay in hours; median (range)

7 (6.4–7.6)

7.5 (5.3–9.8)

4.9 (4.0–6.1)

6.3 (5.2–7.4)

5.4 (4.0–7.1)

4.5 (4.0–6.0)

6.3 (4.9–6.8)

Braak NFT stage (median & range)

2 (1–3)

1 (1)

6 (5–6)

2 (1–2)

1 (1–2)

1 (0–3)

0 (0–1)

CERAD Amyloid Plaque score (median and range)

A (O-B)

A(A-B)

C (C)

O (O-A)

A (O-B)

B (O-B)

A (O-B)

Thal phase for Amyloid [93] (median & range)

1 (0–2)

1 (1)

4 (4–5)

0 (0–2)

2 (0–3)

3 (0–4)

1 (0–2)

Braak LB stage (median and range)

0 (0)

0 (0)

0 (0)

6 (4–6)

6 (4–6)

6 (6)

0 (0)

Brain regions analyzed

HIP, PUT, SN

HIP, PUT, SN

HIP, PUT

HIP, PUT, SN

HIP, PUT, SN

HIP, PUT, SN

HIP, PUT, SN